Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 527

1.

Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.

Lu J, Lee JH, Huang SY, Qiu L, Lee JJ, Liu T, Yoon SS, Kim K, Shen ZX, Eom HS, Chen WM, Min CK, Kim HJ, Lee JO, Kwak JY, Yiu W, Chen G, Ervin-Haynes A, Hulin C, Facon T.

Br J Haematol. 2017 Jan 20. doi: 10.1111/bjh.14465. [Epub ahead of print]

PMID:
28106903
2.

Second-line rituximab, lenalidomide, and bendamustine (R2B) in mantle cell lymphoma: a phase 2 clinical trial of the Fondazione Italiana Linfomi.

Zaja F, Ferrero S, Stelitano C, Ferrari A, Salvi F, Arcari A, Musuraca G, Botto B, Spina M, Cellini C, Patti C, Liberati AM, Minotto C, Pileri SA, Ceccarelli M, Volpetti S, Ferranti A, Drandi D, Montechiarello E, Ladetto M, Carmichael J, Fanin R.

Haematologica. 2017 Jan 12. pii: haematol.2016.154211. doi: 10.3324/haematol.2016.154211. [Epub ahead of print] No abstract available.

3.

Implementation of a novel ultra fast metabolic stability analysis method using exact mass TOF-MS.

Manna JD, Richardson SJ, Moghaddam MF.

Bioanalysis. 2017 Jan 11. doi: 10.4155/bio-2016-0187. [Epub ahead of print]

PMID:
28074669
4.

Effectiveness of Risk Evaluation and Mitigation Strategies (REMS) for Lenalidomide and Thalidomide: Patient Comprehension and Knowledge Retention.

Brandenburg NA, Bwire R, Freeman J, Houn F, Sheehan P, Zeldis JB.

Drug Saf. 2017 Jan 10. doi: 10.1007/s40264-016-0501-2. [Epub ahead of print]

PMID:
28074423
5.

Distinct biodistribution of doxorubicin and the altered dispositions mediated by different liposomal formulations.

Luo R, Li Y, He M, Zhang H, Yuan H, Johnson M, Palmisano M, Zhou S, Sun D.

Int J Pharm. 2017 Jan 4;519(1-2):1-10. doi: 10.1016/j.ijpharm.2017.01.002. [Epub ahead of print]

PMID:
28063903
6.

Mitotic catastrophe and cell cycle arrest are alternative cell death pathways executed by bortezomib in rituximab resistant B-cell lymphoma cells.

Gu JJ, Kaufman GP, Mavis C, Czuczman MS, Hernandez-Ilizaliturri FJ.

Oncotarget. 2016 Dec 31. doi: 10.18632/oncotarget.14405. [Epub ahead of print]

7.

Correlation of antibody responses to a peptide antigen gp120-C5<sup>501-512</sup>/gp41<sup>732-744</sup> with HIV disease progression.

Sørensen B, Sommerfelt MA, Stjernholm G, Smith PL, Ökvist M, Hovden AO, Hoddevik G, Redfield RR, Ustina V, Jelmert Ø, Zeldis J, Dalgleish A.

AIDS Res Hum Retroviruses. 2017 Jan 4. doi: 10.1089/AID.2016.0184. [Epub ahead of print]

PMID:
28051320
8.

Risk stratification, treatment selection, and transplant eligibility in multiple myeloma: a qualitative study of the perspectives and self-reported practices of oncologists.

LeBlanc TW, Howson A, Turell W, Sheldon P, Locke SC, Tuchman SA, Gasparetto C, Kaura S, Khan ZM, Abernethy AP.

Curr Oncol. 2016 Dec;23(6):e598-e604. doi: 10.3747/co.23.3298.

9.

Post-surgical depressive symptoms and long-term survival in non-metastatic breast cancer patients at 11-year follow-up.

Antoni MH, Jacobs JM, Bouchard LC, Lechner SC, Jutagir DR, Gudenkauf LM, Blomberg BB, Glück S, Carver CS.

Gen Hosp Psychiatry. 2017 Jan - Feb;44:16-21. doi: 10.1016/j.genhosppsych.2016.10.002.

PMID:
28041571
10.

Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials.

Shi Q, Flowers CR, Hiddemann W, Marcus R, Herold M, Hagenbeek A, Kimby E, Hochster H, Vitolo U, Peterson BA, Gyan E, Ghielmini M, Nielsen T, De Bedout S, Fu T, Valente N, Fowler NH, Hoster E, Ladetto M, Morschhauser F, Zucca E, Salles G, Sargent DJ.

J Clin Oncol. 2016 Dec 28:JCO2016708651. [Epub ahead of print]

PMID:
28029309
11.

Health-Related Quality of Life in Patients with Metastatic Pancreatic Cancer.

Picozzi V, Narayanan S, Henry Hu X, Vacirca J.

J Gastrointest Cancer. 2016 Dec 28. doi: 10.1007/s12029-016-9902-9. [Epub ahead of print]

PMID:
28028766
12.

Further psychometric validation of the GAH scale: Responsiveness and effect size.

Cruz-Jentoft AJ, González B, de la Rubia J, Hernández Rivas JÁ, Soler JA, Fernández Lago C, Arnao M, Gironella M, Pérez Persona E, Zudaire MT, Olivier C, Altés A, García Guiñón A, Nomdedeu B, Arnan M, Ramírez Payer Á, Sánchez-Godoy P, Pajuelo N, Vilanova D, Monjil DF, Bonanad S; GAH Group..

J Geriatr Oncol. 2016 Dec 22. pii: S1879-4068(16)30173-4. doi: 10.1016/j.jgo.2016.12.008. [Epub ahead of print]

PMID:
28017687
13.

A noninterventional observational registry of patients with multiple myeloma treated with lenalidomide in Taiwan.

Huang SY, Yu YB, Yeh SP, Chen TY, Kao WY, Chen CC, Wang MC, Lin HY, Lin SF, Lin TH, Hua Y, Puccio-Pick M, DeMarco D, Jacques C, Dunn P.

J Formos Med Assoc. 2016 Dec 21. pii: S0929-6646(16)30393-X. doi: 10.1016/j.jfma.2016.11.005. [Epub ahead of print]

14.

Trends in overall survival and costs of multiple myeloma, 2000-2014.

Fonseca R, Abouzaid S, Bonafede M, Cai Q, Parikh K, Cosler L, Richardson P.

Leukemia. 2017 Jan 20. doi: 10.1038/leu.2016.380. [Epub ahead of print]

PMID:
28008176
15.

Pancreatic Cancer Management and Treatment Landscape Awareness of Gastroenterologists: Results from US Physician Surveys Conducted in 2013 and 2015.

Salinas GD, Whitworth L, Merwin P, Emarine J.

J Gastrointest Cancer. 2016 Dec 22. doi: 10.1007/s12029-016-9906-5. [Epub ahead of print]

PMID:
28005258
16.

Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis.

Wilkerson J, Abdallah K, Hugh-Jones C, Curt G, Rothenberg M, Simantov R, Murphy M, Morrell J, Beetsch J, Sargent DJ, Scher HI, Lebowitz P, Simon R, Stein WD, Bates SE, Fojo T.

Lancet Oncol. 2017 Jan;18(1):143-154. doi: 10.1016/S1470-2045(16)30633-7.

PMID:
27979599
17.

PS01.79: Epidemiology and Characteristics of US Veterans with NSCLC Using US Veterans Affairs (VA) Database: Topic: Medical Oncology.

Patel MI, Parisi M, Patel M, Pelletier C, Bennett CL, Georgantopoulos P.

J Thorac Oncol. 2016 Nov;11(11S):S320-S321. doi: 10.1016/j.jtho.2016.09.114. No abstract available.

PMID:
27969546
18.

PS01.08: ABOUND.PS2 Interim Safety Results: nab-Paclitaxel/Carboplatin Followed by nab-Paclitaxel in NSCLC Patients with ECOG PS of 2: Topic: Medical Oncology.

Gajra A, Ali H, Amiri KI, Karim NA, Matrana MR, Mulford D, Ong TJ, Sanford A, Santos ES, Socinski MA, Spigel DR.

J Thorac Oncol. 2016 Nov;11(11S):S274. doi: 10.1016/j.jtho.2016.09.044. No abstract available.

PMID:
27969477
19.

MINI01.20: Interim Quality of Life (QoL) Results from ABOUND.sqm: nab-Paclitaxel/Carboplatin Induction Therapy in Squamous (SCC) NSCLC: Topic: Medical Oncology.

Thomas M, Page R, Gressot L, Daniel D, Morgensztern D, Levy B, Hussein M, Razaq M, Villaflor VM, Aix SP, Sivarajan K, Engel-Riedel W, Staib P, Ko A, Ong TJ, Trunova N, Spigel DR.

J Thorac Oncol. 2016 Nov;11(11S):S269. doi: 10.1016/j.jtho.2016.09.035. No abstract available.

PMID:
27969468
Items per page

Supplemental Content

Loading ...
Support Center